tiprankstipranks
Incyte initiated with a Neutral at Cantor Fitzgerald
PremiumThe FlyIncyte initiated with a Neutral at Cantor Fitzgerald
2d ago
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
PremiumThe Fly
Incyte gets payment from CMS Skinhealth for povorcitinib commercialization
24d ago
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
PremiumThe Fly
Incyte, CMS enter collaboration, license agreement for povorcitinib in China
24d ago
Incyte to hold a conference call
PremiumThe FlyIncyte to hold a conference call
1M ago
Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
PremiumThe Fly
Incyte announces new data from Phase 2 study evaluating ruxolitinib cream
2M ago
Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
PremiumThe Fly
Incyte presents late-breaking data from Phase 2 trial evaluating povorcitinib
2M ago
Incyte price target raised to $65 from $63 at RBC Capital
PremiumThe FlyIncyte price target raised to $65 from $63 at RBC Capital
2M ago
Incyte price target raised to $68 from $67 at Stifel
PremiumThe Fly
Incyte price target raised to $68 from $67 at Stifel
2M ago
Incyte price target lowered to $84 from $91 at Truist
PremiumThe Fly
Incyte price target lowered to $84 from $91 at Truist
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100